Biofusion Launches Absynth Biologics to Focus on New Treatments for MRSA infection
Biofusion plc, the university IP commercialisation company, announced the launch of a new portfolio company, Absynth Biologics Ltd, which will develop vaccines and antibodies to treat infections caused by the bacterium Staphylococcus aureus (S. aureus) including its more difficult-to-treat drug-resistant form, methicillin-resistant S. aureus (MRSA).
Biofusion has agreed to invest up to £325,000 in the Company to enable it to produce lead vaccine and therapeutic antibody candidates to begin the clinical trial process. Absynth's unique patented technology has been developed at the University of Sheffield and will be used to develop an MSRA vaccine and antibodies to treat significant MRSA related infections as well as other applications.
In accordance with all its new spin-out companies, Biofusion owns 100% of the university's share in Absynth, resulting in a 60% shareholding on incorporation.
The launch of Absynth brings the total number of companies in the Biofusion portfolio to 22, 15 based on research from the University of Sheffield and seven based on research from Cardiff University.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous